Next Science Limited announced that it has signed a US distribution agreement with Zimmer, Inc. for XPERIENCE, Next Science's proprietary leave-in surgical wash. Integral to this, Zimmer has withdrawn the complaint which was referenced in Next Science's announcement made on 24 June 2021. The parties have also agreed a refreshed distribution arrangement for Bactisure.

Next Science and Zimmer have executed a distribution agreement for Zimmer to sell a white labelled version of XPERIENCE into the US market under Zimmer's own labelling. The agreement is effective immediately and has a 5 year term plus a 5 year renewal option. Importantly, the agreement confirms Next Science's intellectual property ownership and rights in respect of XPERIENCE.

Next Science expects the revenues received from sales of the Zimmer white label XPERIENCETM product to become material. Zimmer's joint replacement sales team of approximately 2000 staff will be responsible for selling Zimmer's white label version of XPERIENCETM, with the US product launch expected in H2. Zimmer is a world leader in orthopaedic surgery, including hip and knee replacement surgery.

It holds the large market share position (based on revenue) in the US joint replacement market. Zimmer's access to the white label XPERIENCETM product allows it to address the large preventative infection control market in joint replacement surgery. Zimmer has been distributing Bactisure in the US market and building a following for XBIOTM brand as an answer to the biofilms and bacteria that directly lead to the need for revision (repeat) joint replacement surgeries.

Zimmer will continue to sell Bactisure in the US under refreshed arrangements. The revised Bactisure arrangements include a revised agreement term. The term will end on 31 December 2026 with Zimmer having the option to extend the agreement for an additional five year period by providing 6 months' prior notice.

In conjunction with the signing of the new XPERIENCE distribution agreement, Zimmer has dismissed the complaint which was referenced in Next Science's ASX announcement of 24 June 2021.